Contracts & Pricing June 29, 2021 SPTR, CMS Final Rule & VA Public Law Updates 5 Minute Read The latest regulatory updates and reporting reminders for June 2021.
Contracts & Pricing May 27, 2021 Making Sense of Co-Pay Offset Programs 4 Minute Read We dive into the specifics of co-pay offset programs and also examine updates to 340B administrative dispute resolution and ASP reporting as per H.R. 133.
Contracts & Pricing April 21, 2021 Updates to State Price Transparency Reporting, Medicaid Laws 3 Minute Read Stay up-to-date with relevant, timely industry insights and regulatory updates that may impact pharmaceutical manufacturers.
Contracts & Pricing March 11, 2021 Changes to Medicare Part D, Drug Rebate Program, OIG Final Rule 5 Minute Read Stay up-to-date with relevant, timely industry insights and regulatory updates that may impact pharmaceutical manufacturers.
Contracts & Pricing February 16, 2021 New ASP Reporting Requirements, 340B Drug Pricing Program and Final Rule,... 4 Minute Read Stay up-to-date with relevant, timely industry insights and regulatory updates that may impact pharmaceutical manufacturers.
Contracts & Pricing October 15, 2020 Public Law Timeline for 2021, OIG Audit Report, Hot Topics at... 2 Minute Read Stay up-to-date with relevant, timely industry insights and regulatory updates that may impact pharmaceutical manufacturers.
Contracts & Pricing September 17, 2020 Additional Drug Reporting for NDA and ANDA Holders, FDA NSDE Structured... 2 Minute Read Stay up-to-date with relevant, timely industry insights and regulatory updates that may impact pharmaceutical manufacturers.
Contracts & Pricing August 11, 2020 New Drug Pricing Executive Orders, Changes to 340B 2 Minute Read Stay up-to-date with relevant, timely industry insights and regulatory updates that may impact pharmaceutical manufacturers.
Contracts & Pricing July 22, 2020 New News From California: Pricing Transparency, State Supplemental Program 2 Minute Read Stay up-to-date with relevant, timely industry insights and regulatory updates that may impact pharmaceutical manufacturers.
